{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:35:00Z","timestamp":1787020500440,"version":"build-2736575974"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T00:00:00Z","timestamp":1655683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T00:00:00Z","timestamp":1655683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Latvian National Fundamental and Applied Research","award":["lzp-2018\/1-0143"],"award-info":[{"award-number":["lzp-2018\/1-0143"]}]},{"DOI":"10.13039\/501100005632","name":"Narodowe Centrum Bada\u0144 i Rozwoju","doi-asserted-by":"publisher","award":["STRATEGMED1\/233226\/11\/NCBR\/2015"],"award-info":[{"award-number":["STRATEGMED1\/233226\/11\/NCBR\/2015"]}],"id":[{"id":"10.13039\/501100005632","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Protein disulphide isomerases (PDIs) play an important role in cancer progression. However, the relative contribution of the various isoforms of PDI in tumorigenesis is not clear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The content of PDI isoforms in 22 cancer cells lines was investigated using LC\u2013MS\/MS-based proteomic analysis. The effects of PDIA1, PDIA3 and PDIA17 inhibition on the proliferation, migration and adhesion of MCF-7 and MDA-MB-231 cells, identified as high and low PDIA17 expressing cells, respectively, were assessed using novel aromatic N-sulphonamides of aziridine-2-carboxylic acid derivatives as PDI inhibitors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>PDIA1 and PDIA3 were the most abundant in cancer cell lysates and were also detected extracellularly in breast cancer cells (MDA-MB-231 and MCF-7). Some cancer cell lines (e.g., MCF-7, HT-29) showed upregulated expression of PDIA17, whereas in others (e.g., MDA-MB-231, 67NR), PDIA17 was not detected. The simultaneous inhibition of PDIA1 and PDIA3 showed similar anti-proliferative effects in MCF-7 and MDA-MB-231 breast cancer cells. However, the inhibition of PDIA1 and PDIA17 in the MCF-7 cell line resulted in more effective anti-adhesive and anti-proliferative effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PDIA1 and PDIA3 represent major isoforms of multiple cancer cells, and their non-selective inhibition displays significant anti-proliferative effects irrespective of whether or not PDIA17 is present. The more pronounced anti-adhesive effects of PDI inhibition in hormone-sensitive MCF-7 cells featured by higher levels of PDIs when compared to triple-negative MDA-MB-231 cells suggests that targeting extracellular PDIA1 and PDIA3 with or without additional PDIA17 inhibition may represent a strategy for personalized anti-adhesive, anti-metastatic therapy in cancers with high PDI expression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12935-022-02631-w","type":"journal-article","created":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T01:03:06Z","timestamp":1655686986000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Comparison of anti-cancer effects of novel protein disulphide isomerase (PDI) inhibitors in breast cancer cells characterized by high and low PDIA17 expression"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2130-0099","authenticated-orcid":false,"given":"Anna","family":"Kurpi\u0144ska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0190-2474","authenticated-orcid":false,"given":"Joanna","family":"Suraj-Pra\u017cmowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2291-4068","authenticated-orcid":false,"given":"Marta","family":"Stojak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9287-6207","authenticated-orcid":false,"given":"Joanna","family":"Jarosz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8234-3346","authenticated-orcid":false,"given":"\u0141ukasz","family":"Mateuszuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7310-1556","authenticated-orcid":false,"given":"Ewa","family":"Niedzielska-Andres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1619-0913","authenticated-orcid":false,"given":"Magdalena","family":"Smolik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4980-6606","authenticated-orcid":false,"given":"Joanna","family":"Wietrzyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6076-7818","authenticated-orcid":false,"given":"Ivars","family":"Kalvins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5670-9866","authenticated-orcid":false,"given":"Maria","family":"Walczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2878-3858","authenticated-orcid":false,"given":"Stefan","family":"Ch\u0142opicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,20]]},"reference":[{"issue":"2","key":"2631_CR1","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/jcp.10172","volume":"193","author":"C Turano","year":"2002","unstructured":"Turano C, Coppari S, Altieri F, Ferraro A. Proteins of the PDI family: unpredicted non-ER locations and functions. J Cell Physiol. 2002;193(2):154\u201363.","journal-title":"J Cell Physiol"},{"issue":"29","key":"2631_CR2","doi-asserted-by":"publisher","first-page":"6282","DOI":"10.1021\/bi100753s","volume":"49","author":"V Gonzalez","year":"2010","unstructured":"Gonzalez V, Pal R, Narayan M. The oxidoreductase behavior of protein disulfide isomerase impedes fold maturation of endoplasmic reticulum-processed proteins in the pivotal structure-coupled step of oxidative folding: implications for subcellular protein trafficking. Biochemistry. 2010;49(29):6282\u20139.","journal-title":"Biochemistry"},{"issue":"8","key":"2631_CR3","doi-asserted-by":"publisher","first-page":"401","DOI":"10.5483\/BMBRep.2017.50.8.107","volume":"50","author":"E Lee","year":"2017","unstructured":"Lee E, Lee DH. Emerging roles of protein disulfide isomerase in cancer. BMB Rep. 2017;50(8):401\u201310.","journal-title":"BMB Rep"},{"key":"2631_CR4","first-page":"70","volume":"2","author":"HA Khan","year":"2014","unstructured":"Khan HA, Mutus B. Protein disulfide isomerase a multifunctional protein with multiple physiological roles. Front Chem. 2014;2:70.","journal-title":"Front Chem"},{"key":"2631_CR5","doi-asserted-by":"publisher","first-page":"74605","DOI":"10.1039\/C5RA08551A","volume":"5","author":"G Cui","year":"2015","unstructured":"Cui G, Shan L, Chu IK, Li G, Leung GPK, Wang Y, et al. Identification of disulfide isomerase ERp57 as a target for small molecule cardioprotective agents. RSC Adv. 2015;5:74605\u201310.","journal-title":"RSC Adv"},{"issue":"8","key":"2631_CR6","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1091\/mbc.10.8.2573","volume":"10","author":"JD Oliver","year":"1999","unstructured":"Oliver JD, Roderick HL, Llevellyn DH, High S. Erp57 functions as a subunit of specific complexes formed with the ER lectins calreticulin and calnexin. Mol Biol Cell. 1999;10(8):2573\u201382.","journal-title":"Mol Biol Cell"},{"key":"2631_CR7","doi-asserted-by":"publisher","first-page":"14151","DOI":"10.1038\/ncomms14151","volume":"8","author":"SR Bowley","year":"2017","unstructured":"Bowley SR, Fang C, Merrill-Skoloff G, Furie BC, Furie B. Protein disulfide isomerase secretion following vascular injury initiates a regulatory pathway for thrombus formation. Nature Commun. 2017;8:14151.","journal-title":"Nature Commun"},{"key":"2631_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.pharmthera.2017.07.011","volume":"181","author":"A Hettinghouse","year":"2018","unstructured":"Hettinghouse A, Liu R, Liu C-J. Multifunctional molecule ERp57: From cancer to neurodegenerative diseases. Pharmacol Ther. 2018;181:34\u201348.","journal-title":"Pharmacol Ther"},{"key":"2631_CR9","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.2741\/4663","volume":"23","author":"H Ponamarczuk","year":"2018","unstructured":"Ponamarczuk H, Popielarski M, Stasiak M, Bednarek R, Studzian M, Pulaski L, et al. Contribution of activated beta3 integrin in the PDI release from endothelial cells. Front Biosci. 2018;23:1612\u201327.","journal-title":"Front Biosci"},{"issue":"3","key":"2631_CR10","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.drudis.2013.10.017","volume":"19","author":"S Xu","year":"2014","unstructured":"Xu S, Sankar S, Neamati N. Protein disulfide isomerase: a promising target for cancer therapy. Drug Discov Today. 2014;19(3):222\u201340.","journal-title":"Drug Discov Today"},{"issue":"10","key":"2631_CR11","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.3390\/cancers12102850","volume":"12","author":"M Stojak","year":"2020","unstructured":"Stojak M, Milczarek M, Kurpinska A, Suraj-Prazmowska J, Kaczara P, Wojnar-Lason K, et al. Protein disulphide isomerase A1 is involved in the regulation of breast cancer cell adhesion and transmigration via lung microvascular endothelial cells. Cancers. 2020;12(10):2850.","journal-title":"Cancers"},{"issue":"61","key":"2631_CR12","doi-asserted-by":"publisher","first-page":"103543","DOI":"10.18632\/oncotarget.21569","volume":"8","author":"S Samanta","year":"2017","unstructured":"Samanta S, Tamura S, Dubeau L, Mhawech-Fauceglia P, Miyagi Y, Kato H, et al. Expression of protein disulfide isomerase family members correlates with tumor progression and patient survival in ovarian cancer. Oncotarget. 2017;8(61):103543\u201356.","journal-title":"Oncotarget"},{"key":"2631_CR13","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.canlet.2019.01.025","volume":"449","author":"H Negi","year":"2019","unstructured":"Negi H, Merugu SB, Mangukiya HB, Li Z, Zhou B, Sehar Q, et al. Anterior Gradient-2 monoclonal antibody inhibits lung cancer growth and metastasis by upregulating p53 pathway and without exerting any toxicological effects: a preclinical study. Cancer Lett. 2019;449:125\u201334.","journal-title":"Cancer Lett"},{"key":"2631_CR14","doi-asserted-by":"publisher","first-page":"3458","DOI":"10.1038\/s41388-019-0675-z","volume":"38","author":"D Wang","year":"2019","unstructured":"Wang D, Xu Q, Yuan Q, Jia M, Niu H, Liu X, et al. Proteasome inhibition boosts autophagic degradation of ubiquitinated-AGR2 and enhances the antitumor efficiency of bevacizumab. Oncogene. 2019;38:3458\u201374.","journal-title":"Oncogene"},{"issue":"6","key":"2631_CR15","doi-asserted-by":"publisher","first-page":"4896","DOI":"10.3892\/ol.2016.5304","volume":"12","author":"H Takata","year":"2016","unstructured":"Takata H, Kudo M, Yamamoto T, Ueda J, Ishino K, Peng W-X, et al. Increased expression of PDIA3 and its association with cancer cell proliferation and poor prognosis in hepatocellular carcinoma. Oncol Lett. 2016;12(6):4896\u2013904.","journal-title":"Oncol Lett"},{"issue":"2","key":"2631_CR16","first-page":"501","volume":"39","author":"H Zou","year":"2018","unstructured":"Zou H, Wen C, Peng Z, Shao Y-Y, Hu L, Li S, et al. P4HB and PDIA3 are associated with tumor progression and therapeutic outcome of diffuse gliomas. Oncol Rep. 2018;39(2):501\u201310.","journal-title":"Oncol Rep"},{"key":"2631_CR17","first-page":"4964","volume":"18","author":"A Martisova","year":"2019","unstructured":"Martisova A, Sommerova L, Kuricova K, Podhorec J, Vojtesek B, Kankova K, et al. AGR2 silencing contributes to metformin-dependent sensitization of colorectal cancer cells to chemotherapy. Oncol Lett. 2019;18:4964\u201373.","journal-title":"Oncol Lett"},{"issue":"7","key":"2631_CR18","doi-asserted-by":"publisher","first-page":"E890","DOI":"10.3390\/cancers11070890","volume":"11","author":"R Alsereihi","year":"2019","unstructured":"Alsereihi R, Schulten H-J, Bakhashab S, Saini K, Al-Hejin AM, Hussein D. Leveraging the role of the metastatic associated protein anterior gradient homologue 2 in unfolded protein degradation: a novel therapeutic biomarker for cancer. Cancers. 2019;11(7):E890.","journal-title":"Cancers"},{"key":"2631_CR19","unstructured":"Kalvins I, Chlopicki S, Andrianov V, Stojak M, Domraceva I, Kanepe-Lapsa I et al. Aromatic sulphonamides derivatives that inhibits PDIA1, their synthesis and use. Patent no.: WO\/2021\/141506. 2021."},{"key":"2631_CR20","unstructured":"Chlopicki S, Kalvins I, Przyborowski K, Stojak M, Andrianov V, Domraceva I et al. Aromatic sulphonamides derivatives that inhibits PDIA3, their synthesis and use. Patent no.: WO\/2021\/141507. 2021."},{"key":"2631_CR21","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/978-1-61779-885-6_16","volume":"893","author":"B Sitek","year":"2012","unstructured":"Sitek B, Waldera-Lupa DM, Poschmann G, Meyer HE, St\u00fchler K. Application of label-free proteomics for differential analysis of lung carcinoma cell line A549. Methods Mol Biol. 2012;893:241\u20138.","journal-title":"Methods Mol Biol"},{"key":"2631_CR22","doi-asserted-by":"crossref","unstructured":"Boschetti E, Righetti PG. Detailed methodologies and protocols. In: Low-abundance proteome discovery: state of the art and protocols. Elsevier, 2013.","DOI":"10.1016\/B978-0-12-401734-4.00008-7"},{"key":"2631_CR23","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.yexmp.2019.02.001","volume":"107","author":"A Kurpi\u0144ska","year":"2019","unstructured":"Kurpi\u0144ska A, Suraj J, Bonar E, Zakrzewska A, Stojak M, Sternak M, et al. Proteomic characterization of early lung response to breast cancer metastasis in mice. Exp Mol Pathol. 2019;107:129\u201340.","journal-title":"Exp Mol Pathol"},{"key":"2631_CR24","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1074\/mcp.M500061-MCP200","volume":"4","author":"Y Ishihama","year":"2005","unstructured":"Ishihama Y, Oda Y, Tabata T, Sato T, Nagasu T, Rappsilber J, et al. Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein. Mol Cell Proteomics. 2005;4:1265\u201372.","journal-title":"Mol Cell Proteomics"},{"issue":"9","key":"2631_CR25","doi-asserted-by":"publisher","first-page":"e0183930","DOI":"10.1371\/journal.pone.0183930","volume":"12","author":"J Roy","year":"2017","unstructured":"Roy J, Wycislo KL, Pondenis H, Fan TM, Das A. Comparative proteomic investigation of metastatic and non-metastatic osteosarcoma cells of human and canine origin. PLoS ONE. 2017;12(9):e0183930.","journal-title":"PLoS ONE"},{"key":"2631_CR26","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.1016\/j.jprot.2012.05.030","volume":"75","author":"A Malinowska","year":"2012","unstructured":"Malinowska A, Kistowski M, Bakun M, Rubel T, Tkaczyk M, Mierzejewska J, et al. Diffprot-software for non-parametric statistical analysis of differential proteomics data. J Proteomics. 2012;75:4062\u201373.","journal-title":"J Proteomics"},{"issue":"1","key":"2631_CR27","first-page":"144","volume":"5","author":"JC Silva","year":"2006","unstructured":"Silva JC, Gorenstein MV, Li G-Z, Vissers JPC, Geromanos SJ. Absolute quantification of proteins by LCMS: a virtue of parallel ms acquisition. MCP. 2006;5(1):144\u201356.","journal-title":"MCP"},{"key":"2631_CR28","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ejmech.2017.03.028","volume":"132","author":"M Psurski","year":"2017","unstructured":"Psurski M, Janczewski \u0141, \u015awitalska M, Gajda A, Goszczy\u0144ski TM, Oleksyszyn J, et al. Novel phosphonate analogs of sulforaphane: Synthesis, in vitro and in vivo anticancer activity. Eur J Med Chem. 2017;132:63\u201380.","journal-title":"Eur J Med Chem"},{"issue":"8","key":"2631_CR29","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1002\/cam4.3836","volume":"10","author":"LE Powell","year":"2021","unstructured":"Powell LE, Foster PA. Protein disulphide isomerase inhibition as a potential cancer therapeutic strategy. Cancer Med. 2021;10(8):2812\u201325.","journal-title":"Cancer Med"},{"issue":"Pt 16","key":"2631_CR30","first-page":"3649","volume":"126","author":"H Dihazi","year":"2013","unstructured":"Dihazi H, Dihazi GH, Bibi A, Eltoweissy M, Mueller CA, Asif AR, et al. Secretion of ERP57 is important for extracellular matrix accumulation and progression of renal fibrosis, and is an early sign of disease onset. J Cell Sci. 2013;126(Pt 16):3649\u201363.","journal-title":"J Cell Sci"},{"issue":"5","key":"2631_CR31","first-page":"5753","volume":"16","author":"KM Kim","year":"2018","unstructured":"Kim KM, An AR, Park HS, Jang KY, Moon WS, Kang MJ, et al. Combined expression of protein disulfide isomerase and endoplasmic reticulum oxidoreductin 1-\u03b1 is a poor prognostic marker for non-small cell lung cancer. Oncol Lett. 2018;16(5):5753\u201360.","journal-title":"Oncol Lett"},{"issue":"4","key":"2631_CR32","doi-asserted-by":"publisher","first-page":"125851","DOI":"10.1172\/jci.insight.125851","volume":"4","author":"JI Zwicker","year":"2019","unstructured":"Zwicker JI, Schlechter BL, Stopa JD, Liebman HA, Aggarwal A, Puligandla M, et al. Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer. JCI Insight. 2019;4(4):125851.","journal-title":"JCI Insight"},{"issue":"1","key":"2631_CR33","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1186\/s13046-019-1453-z","volume":"38","author":"Y Liu","year":"2019","unstructured":"Liu Y, Wang JX, Nie ZY, Wen Y, Jia XJ, Zhang LN, et al. Upregulation of ERp57 promotes clear cell renal cell carcinoma progression by initiating a STAT3\/ILF3 feedback loop. J Exp Clin Cancer Res. 2019;38(1):439.","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"2631_CR34","first-page":"1409","volume":"54","author":"R Kondo","year":"2019","unstructured":"Kondo R, Ishino K, Wada R, Takata H, Peng WX, Kudo M, et al. Downregulation of protein disulfide-isomerase A3 expression inhibits cell proliferation and induces apoptosis through STAT3 signaling in hepatocellular carcinoma. Int J Oncol. 2019;54(4):1409\u201321.","journal-title":"Int J Oncol"},{"key":"2631_CR35","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s12276-019-0358-4","volume":"52","author":"L Hell","year":"2020","unstructured":"Hell L, Lurger K, Mauracher LM, Grilz E, Reumiller CM, Schmidt GJ, et al. Altered platelet proteome in lupus anticoagulant (LA)-positive patients\u2014protein disulfide isomerase and NETosis as new players in LA-related thrombosis. Exp Mol Med. 2020;52:66\u201378.","journal-title":"Exp Mol Med"},{"key":"2631_CR36","doi-asserted-by":"publisher","first-page":"e13887","DOI":"10.7554\/eLife.13887","volume":"5","author":"D Fessart","year":"2016","unstructured":"Fessart D, Domblides C, Avril T, Eriksson LA, Begueret H, Pineau R, et al. Secretion of protein disulphide isomerase AGR2 confers tumorigenic properties. Elife. 2016;5:e13887.","journal-title":"Elife"},{"issue":"5","key":"2631_CR37","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.2353\/ajpath.2009.090246","volume":"175","author":"DL Barraclough","year":"2009","unstructured":"Barraclough DL, Platt-Higgins A, de Silva RS, Barraclough R, Winstanley J, West CR, et al. The metastasis-associated anterior gradient 2 protein is correlated with poor survival of breast cancer patients. Am J Pathol. 2009;175(5):1848\u201357.","journal-title":"Am J Pathol"},{"issue":"12","key":"2631_CR38","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1042\/CS20090537","volume":"118","author":"TA Edgell","year":"2010","unstructured":"Edgell TA, Barraclough DL, Rajic A, Dhulia J, Lewis KJ, Armes JE, et al. Increased plasma concentrations of anterior gradient 2 protein are positively associated with ovarian cancer. Clin Sci. 2010;118(12):717\u201325.","journal-title":"Clin Sci"},{"key":"2631_CR39","first-page":"4025","volume":"24","author":"OCH Kousidou","year":"2004","unstructured":"Kousidou OCH, Roussidis AE, Theocharis AD, Karamanos MK. Expression of MMPs and TIMPs genes in human breast cancer epithelial cells depends on cell culture conditions and is associated with their invasive potential. Anticancer Res. 2004;24:4025\u201330.","journal-title":"Anticancer Res"},{"key":"2631_CR40","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.semcancer.2015.04.005","volume":"33","author":"V Brychtova","year":"2015","unstructured":"Brychtova V, Mohtar A, Vojtesek B, Hupp TR. Mechanisms of anterior gradient-2 regulation and function in cancer. Semin Cancer Biol. 2015;33:16\u201324.","journal-title":"Semin Cancer Biol"},{"issue":"4","key":"2631_CR41","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.bbrc.2019.05.154","volume":"515","author":"B Dahal Lamichane","year":"2019","unstructured":"Dahal Lamichane B, Jung SY, Yun J, Kang S, Kim DY, Lamichane S, et al. AGR2 is a target of canonical Wnt\/\u03b2-catenin signaling and is important for stemness maintenance in colorectal cancer stem cells. Biochem Biophys Res Commun. 2019;515(4):600\u20136.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"2631_CR42","doi-asserted-by":"publisher","first-page":"C40","DOI":"10.1152\/ajpcell.00532.2018","volume":"318","author":"F Delom","year":"2020","unstructured":"Delom F, Mohtar MA, Hupp T, Fessart D. The anterior gradient-2 interactome. Am J Physiol Cell Physiol. 2020;318(1):C40\u20137.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"9","key":"2631_CR43","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1210\/me.2006-0006","volume":"20","author":"JR Schultz-Norton","year":"2006","unstructured":"Schultz-Norton JR, Hayes McDonald W, Yates JR, Nardulli AM. Protein disulfide isomerase serves as a molecular chaperone to maintain estrogen receptor \u03b1 structure and function. Mol Endocrinol. 2006;20(9):1982\u201395.","journal-title":"Mol Endocrinol"},{"issue":"3","key":"2631_CR44","doi-asserted-by":"publisher","first-page":"R32","DOI":"10.1186\/bcr2586","volume":"12","author":"KE Vanderlaag","year":"2010","unstructured":"Vanderlaag KE, Hudak S, Bald L, Fayadat-Dilman L, Sathe M, Grein J, et al. Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivin. Breast Cancer Res. 2010;12(3):R32.","journal-title":"Breast Cancer Res"},{"issue":"5","key":"2631_CR45","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1111\/febs.12118","volume":"280","author":"H Bu","year":"2013","unstructured":"Bu H, Schweiger MR, Manke T, Wunderlich A, Timmermann B, Kerick M, et al. Anterior gradient 2 and 3\u2013two prototype androgen-responsive genes transcriptionally upregulated by androgens and by oestrogens in prostate cancer cells. FEBS J. 2013;280(5):1249\u201366.","journal-title":"FEBS J"},{"issue":"2","key":"2631_CR46","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/cmdc.201700629","volume":"13","author":"A Kyani","year":"2018","unstructured":"Kyani A, Tamura S, Yang S, et al. Discovery and mechanistic elucidation of a class of protein disulfide isomerase inhibitors for the treatment of glioblastoma. Chem Med Chem. 2018;13(2):164\u201377.","journal-title":"Chem Med Chem"},{"issue":"40","key":"2631_CR47","doi-asserted-by":"publisher","first-page":"16348","DOI":"10.1073\/pnas.1205226109","volume":"109","author":"S Xu","year":"2012","unstructured":"Xu S, Butkevich AN, Yamada R, Zhou Y, Debnath B, Duncan R, et al. Discovery of an orally active small-molecule irreversible inhibitor of protein disulfide isomerase for ovarian cancer treatment. Proc Natl Acad Sci USA. 2012;109(40):16348\u201353.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2631_CR48","doi-asserted-by":"publisher","first-page":"110076","DOI":"10.1016\/j.cellsig.2021.110076","volume":"86","author":"Y-S Ma","year":"2021","unstructured":"Ma Y-S, Feng S, Lin L, Zhang H, Wei G-H, Liu Y-S, et al. Protein disulfide isomerase inhibits endoplasmic reticulum stress response and apoptosis via its oxidoreductase activity in colorectal cancer. Cell Signal. 2021;86:110076.","journal-title":"Cell Signal"},{"issue":"11","key":"2631_CR49","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1158\/0008-5472.CAN-15-3099","volume":"76","author":"S Vatolin","year":"2016","unstructured":"Vatolin S, Phillips JG, Jha BK, Govindgari S, Hu J, Grabowski D, et al. Novel Protein Disulfide Isomerase inhibitor with anticancer activity in multiple myeloma. Cancer Res. 2016;76(11):3340\u201350.","journal-title":"Cancer Res"},{"issue":"4","key":"2631_CR50","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/s41375-018-0263-1","volume":"33","author":"RM Robinson","year":"2019","unstructured":"Robinson RM, Reyes L, Duncan RM, Bian H, Reitz AB, Manevich Y, et al. Inhibitors of the protein disulfide isomerase family for the treatment of multiple myeloma. Leukemia. 2019;33(4):1011\u201322.","journal-title":"Leukemia"},{"issue":"15","key":"2631_CR51","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1111\/bph.15493","volume":"178","author":"X Xu","year":"2021","unstructured":"Xu X, Chiu J, Chen S, Fang C. Pathophysiological roles of cell surface and extracellular protein disulfide isomerase and their molecular mechanisms. Br J Pharmacol. 2021;178(15):2911\u201330.","journal-title":"Br J Pharmacol"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-022-02631-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-022-02631-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-022-02631-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T02:04:25Z","timestamp":1655690665000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-022-02631-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,20]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2631"],"URL":"https:\/\/doi.org\/10.1186\/s12935-022-02631-w","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,20]]},"assertion":[{"value":"20 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"A conflict of interest disclosure statement: SCH, IK, MS, JW have filed a patent on aromatic sulfonamides derivatives that inhibits PDIA1 (WO\/2021\/141506) and PDIA3 (WO\/2021\/141507). Other authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"218"}}